If you paid attention to health social media over the past few years, you've almost certainly felt the confusion. On one side, you have the standard clinical medicine, right? You go in for your routine annual checkup. You get your standard fasting blood work, and a single number on your lipid panel comes back, flagged in red. And within 10 minutes, you're handed a prescription and told you on a direct path towards a heart attack. But in a rushed visit, there is rarely time to unpack why that number matters and what it's doing to your vessels or where these guidelines actually come from.
Then you open your phone. Social media tells you modern cardiology has it all backwards, and for 50 years they've been wrong. You're told cholesterol isn't the problem at all. It's just an innocent firefighter showing up at the scene of a fire. That arterial damage is driven entirely by chronic inflammation, hyperinsulinemia, refined carbs, or seed oils. And if you've listened to both camps and found yourself nodding along to parts of each or simply wondering who on earth to trust, I get it. The conversation has devolved into an ideological war. One side dismisses legitimate patient questions as anti-science ignorance, and the other dismisses a century of vascular biology as a pharma conspiracy. Now, I'm not here to defend clinical guidelines from an ivory tower, and I'm definitely not here to sell you a contrarian view.
My goal is to answer one straightforward question: how did we actually get here? Today, we're going to walk through the scientific evidence brick by brick from the mid-19th century to the modern frontier of human genetics. Not to tell you what to believe, but to give you the complete evidentiary pictures so that you can evaluate the data for yourself and see why modern lipidology arrived at its current consensus. So let's start with the claim that dominates the modern alternative health spaces. Is cardiovascular disease fundamentally an artifact of modern industrial living? It's an intuitive, compelling argument. For roughly 99% of human history, our ancestors weren't sitting in ergonomic chairs under fluorescent lights for eight hours a day eating ultra-processed foods or cooking with refined seed oils. They moved constantly, ate wild whole foods, and lived in the sun.
It seems logical to assume that if we simply return to our roots, our arteries would remain pristine. And so, did heart disease only emerge once we were industrialized? Well, not quite. In 1852, Austrian paleopathologist Johann Ziermark, pictured right here, performed an autopsy on the mummified remains of an ancient Egyptian woman. When he sliced into her descending aorta, he did not find clean, supple, elastic tissue. He found dense, calcified plaques embedded directly in the vascular wall. Then in 1911, Sir Mark Armand Rufer examined dozens more Egyptian mummies and noted with shock that vascular disease was just as prevalent in antiquity as it was in modern London. But critics might argue, well, ancient Egyptian elites, aren't they just like today?
They ate rich diets with beer, bread, and honey. Well, fair point. So a study looked at this. The OUR study performed CT scans on 137 mummies across four distinct cultures: ancient Egyptians, ancient Peruvians, ancestral pueblos of the American Southwest, and Unagan hunter-gatherers from the Aleutian Islands. And the Unagin ate diet composed almost entirely of marine mammals, wild fish, and seal oil. And the ancestral Pueblans foraged wild game and farmed primitive corn. Neither group had ever seen refined sugars or industrial seed oils, yet probable or definitive vascular calcifications were documented across all four cultures, scaling directly with age. And we see the exact same reality with Otzi the Iceman, a copper age mountain hunter preserved in ice for almost 5,300 years. And Otzi had high physical activity, forged wild foods, and carried no modern industrial metabolic insults.
Yet, CT scans revealed extensive calcification in his coronary arteries, his carotids, and aorta. So, does this prove that modern lifestyle doesn't matter? Well, of course not. Ancient humans faced lots of burdens. Like wood smoke, recurrent infections, and stress, like we can't imagine. But it proves beyond a shadow of a doubt that arterial plaque is not an exclusive invention of the 20th century. The human artery has possessed this biological vulnerability for thousands of years. So, what's actually inside those disease arteries? Well, that's what scientists were dying to figure out. And in 1755, Swiss physician Albert von Haller dissected disease vessels and found soft yellowish mush, naming it after the Greek athera, meaning porridge or gruel.
And when I hear gruel, all I can think of is Michael Scott, right? Prison Mike, saying, Would you eat gruel? Gruel omelets. If you know, you know, there's a meme right there. But in 1833, Jean-Frédéric Lovestein observed that disease vessels were stiff, fibrous, and calcified. coining arteriosclerosis. Then in nineteen oh four Felix Marjand combined the two terms, calling it atherosclerosis, the porridge and the scar, or the gruel in the scar, I like to say. And so, for decades, pathologists argued over whether it was mechanical clotting or cellular information that caused this.
But staring at a cadaver on an autosy slab can only ever show so much, right? It just shows the end damage. It cannot prove which component started what. So, to understand that, we had to start testing living biology. That experimental shift took place in St. Petersburg, Russia, in about 1908. Physician Alexander Igwatowski fed laboratory rabbits diets rich in whole milk, eggs, and meat, and within months their aortas developed thick, raised lesions strikingly similar to human arthromas.
And Igotowski assumed animal protein was the systemic metabolic toxin that poisoned the vessel lining. But about the same time, German chemist Adolf Whitehouse made an essential biochemical discovery. Human arterial plaques were loaded with massive concentrations of cholesterol. That led to 1913, where Nikolai Nichkow and Simon Chalatov isolated the variables. So instead of feeding the rabbits whole meat or dairy, they fed them pure cholesterol dissolved in simple sunflower oil. No animal protein, no meat, no dairy. And the results? Well, the rabbits developed the exact same severe lipid-packed arterial plaques.
Under the microscope, Anishkao spotted something that altered vascular histology forever. he found that circulating immune cells, specifically macrophages, had penetrated the arterior wall, engorged themselves in circular lipids and swelled into translucent bubbles. He had discovered the foam cell, the universal hallmark of earlier atherosclotic disease. And it looked like an open and shut case, but the medical establishment pushed back, and for good reason, a rabbit is an obligate herbivore. In nature, a rabbit never consumes dietary cholesterol. Its liver has virtually no mechanism to excrete massive circulating cholesterol loads. When fed pure cholesterol, their blood levels didn't rise slightly. They spiked into the thousands of milligrams per deciliter, depositing their eyes, spleen, and skin. And so skeptics rightly ask, does force feeding an herbivore, a nutrient it was never meant to process, tell us anything meaningful about omnivorous human eating on an ordinary diet over a lifetime?
This critique was valid. Experimental animal models established biological plausibility, but they could not prove real-world causation. And so, following World War II, heart disease shifted from an academic debate to an emergency. The issue started to become prevalent in the 40s, and by the 50s, coronary heart disease was responsible for roughly one in every three deaths in the United States. And as I mentioned in a previous podcast, President Eisenhower suffered a sudden heart attack in 1955, and national panics hit in. Clinicians were empty-handed, and for decades the prevailing view had always been fatalism, while the doctors believed that stiffening arteries were simply the rust of life, an inevitable consequence of aging that you could neither prevent nor alter. To find out whether heart attacks were truly random, researchers launched the Framingham Heart Study in 1948, recruiting over 5,000 ordinary men and women in Massachusetts. They measured blood pressure, smoking habits, and circulating blood lipids, tracking them for decades. In 1961, Framingham published its landmark paper, actually coining the term risk factor.
Heart attacks were not striking at random. Those who suffered them consistently shared measurable predictive biomarkers: elevated blood pressure, cigarette smoking, and elevated circulating total cholesterol. And at the same time, once again, we mentioned this in previous videos, international surveys like Ansel Keys ' seven country studies showed that populations with high fat, high cholesterol diets had vastly higher rates of coronary mortality. But scientific skepticism flared again, anchored in a core scientific principle, association is not causation. And the populations with high rates of heart disease weren't just eating more butter, they were driving cars instead of walking, smoking cigarettes, and consuming more refined carbohydrates. Furthermore, inside Framingham, there was significant individual overlap.
Plenty of people with high cholesterol lived to their eighties with clear arteries, and many had heart attacks who had normal numbers. Skeptics raised a profound question: what if cholesterol is merely an innocent bystander, a surrogate marker for systemic inflammation, metabolic dysfunction, or vascular wear and tear? So, based on these initial types of studies, for decades clinical medicine clung to the threshold theory. The idea that cholesterol is completely harmless for the average person and only becomes toxic past an extreme genetic cliff. In 1986, the Multiple Risk Factor Intervention Trial, or Mr. Fit. tested this assumption. They screened over three hundred fifty thousand middle aged men and tracked their cardiovascular mortality over decades.
The data upended the threshold theory entirely. The relationship between circulating cholesterol and coronary death was continuous, graded, and log linear. There was no magic inflection point where risks suddenly switched on, and no baseline where lower levels stopped tracking with lower risk. Nearly half of all coronary deaths occurred in individuals with intermediate cholesterol levels, simply because they represented the vast majority of the population. In 2007, the Prospective Studies Collaboration settled the observational question. They pooled individual participant data from 61 prospective studies encompassing nearly 900,000 adults and over 33,000 vascular events across nearly 12 million person years of observation. Across every band in both men and women, circulating total and LDL cholesterol exhibited a continuous proportional relationship with vascular mortality.
Yet, observational epidemiology has an inescapable Achilles heel, residual confounding. People who naturally have lower cholesterol might exercise more, might eat more fiber, or live in less polluted areas. The classical healthy user bias. Observational cohorts proved correlation across millions of person years, but they could never prove that lowering cholesterol alone changed biological destiny. So, to solve the causal dilemma, researchers had to look inside the microscopic architecture of the vessel wall. For decades, textbooks taught the response to injury hypothesis, that the artery was like a plumbing pipe scraped raw by high blood pressure or smoking, creating an open wound where circulating fats could deposit. Except, modern electron microscopy uncovered an inconvenient physical fact. When early plaques form, the endothelial line is almost always completely intact.
There is no breakdown, no missing tissue. Whatever was starting this disease happened underneath a smooth, unbroken surface. So then in 1995, Kevin John Williams and Ara Tabas published a paradigm shifting response to retention hypothesis idea. The initiating event was not mechanical scraping, it was the physical entrapment of specific lipoprotein particles beneath the endothelial monolayer. The cascade unfolds in three biophysical steps. So, step one, transcytosis. Any level of protein smaller than 70 nanometers, primarily LDL and remnants.
Slips across the endothelial lining via active vesicle-mediated transcytosis. Under normal conditions, they enter and exit back into the bloodstream harmlessly. Step 2 electrostatic retention. The Intima matrix contains structural proteoglycans with negative electrocharges, so negative charges. Athergenic lipoproteins carry APOB100, which has a positively charged domain known as site B. When the particle concentrations or transit times are high enough, positive bonds to negative, and the particle can get trapped. Step 3 then is the inflammatory response. Once trapped, the particle oxidizes.
Overlying endothelial cells then raise chemical distress flags and monocytes invade, converting to macrophages in an attempt to clean up the trapped lipids. Now, how do we know retention is the true initiating cause rather than just an innocent bystander? A team of vascular biologists led by Dr. Jan Bourne ran a creative molecular experiment. They engineered transgemic mice with a single amino acid substitution in ABOB site B. This single charge reversal completely neutralized the particle's ability to bind to arterial protoglycans without affecting its normal metabolic clearance. They put these mutant mice on a high fat diet alongside normal control mice.
Both groups develop identical skyrocketing blood cholesterol levels. The result? Well, normal mice developed severe, widespread atherosclerosis. The mice with the Site B mutation developed virtually no disease. This proved that high circulating cholesterol cannot cause atherosclerosis. unless the particle physically binds to and is retained by the sub endothelial matrix. Thus they concluded that retention precedes inflammation.
So this then leads to the question, why can't the body simply clear the trapped particles? Under normal conditions, cells shut down LDL receptors when they have enough cholesterol. But macrophages in the arterial walls express scavenger receptors that have no off-switches. They gorge continuously on modified APOB particles until they become foam cells. Eventually, these foam cells die, and if clearance mechanisms are overwhelmed, they undergo secondary necrosis, spilling cellular debris and inflammatory cytokines into the wall. This buildup then becomes an expanding necrotic core. Vascular smooth muscle cells migrate to build a collagenous fibrous cap over the core. But As inflammatory macrophages release matrix metalloproteinases that chew through the collagen, this cap thins.
Under pulsatile arterial stress, the cap ruptures, exposing the thrombogenic core to circulating blood, forming an occlusive clot, which becomes a heart attack or a stroke. So, by the late 1990s, we had cell culture mechanisms and population correlations. But critics still held an undeniable argument: human epidemiology is confounded by lifestyle, and a cell in a petri dish does not represent an 80-year human life. And so to settle this debate with absolute causal certainty, you need to run an impossible trial. Randomize millions of healthy infants at birth to lifelong, low versus lifetime high cholesterol. force them to keep every other lifestyle factor completely identical diet, exercise, stress, sleep, and follow them for 80 years. That trial obviously can't be run.
But as human genomics exploded in the early two thousands, geneticists realized that nature had already run this for us. That framework is called Mendelian randomization. See, when you were conceived, you received a random assortment of genetic variants from your parents. This meiotic shuffle acts just like a double-blind randomized trial before you were ever born. Some individuals inherit common genetic variants that cause their livers to clear circulating lipoproteins slightly more efficiently, resulting in lifelong lower cholesterol. Others inherit variants that keep them slightly higher. Because its genetic allocation happens at conception, it is completely uncoupled from lifestyle. A gene variant doesn't care if you grow up to eat junk food or run marathons. It is immune to healthy user bias.
Socioeconomic confounding and reverse causation. It's nature's lifelong clinical trial. The power of this framework was demonstrated in a landmark 2006 paper in the New England Journal of Medicine by Jonathan Cohen et al. They examined individuals in the arteriosclerosis risk and community study who carried natural loss of function mutations with the PCSKN hygiene. So African American participants with these nonsense mutations had a modest 28 to 40 percent lifelong reduction in circulating LDL cholesterol. So according to short-term adult trials, a 30% drop in LDL should reduce heart disease by about 20 to 25 percent. But when that lower level was present from conception across a lifetime, it produced an astounding 88% reduction in the 15-year cumulative incidence of coronary heart diseases.
A modest reduction in particles maintained over decades practically eliminated coronary events. So a question some people had was: how do we know Mendelian randomization isn't just finding more statistical coincidences? That's a fair question. And another study that looked at one of cardiology's most beloved assumptions that HGL was protective seemed to also point in the same direction. So, for 40 years, observational studies showed that people with a quote-unquote good HGL cholesterol had fewer heart attacks. Pharma spent billions developing drugs to raise HDL. But in 2012, Benjamin Voigt and the International Consortium published a massive Mendelian radarization study in The Lancet. They use a genetic variant in the endothelial lipase gene that selectively raises HDL cholesterol by substantial margins without affecting LDL or triglycerides. And so the result?
Having genetically higher HDL provided zero reduction in myocardial infarctions. And when they looked at genetically high LDL, they saw the same things they witnessed in epidemiologic studies. And increase in heart disease. So, based on this, they thought that HGL had actually been an innocent bystander all along, a marker of metabolic health, but not a causal predictor. And they felt the genetic tools were rigorous enough to separate true causes from confounding surrogates. So, when you compile all the Mendelian randomization data across millions of person years, evaluating genes like the HMG coA reductase, NPC101, and LDL receptor, a profound biological principle emerges. So in a standard five-year medication trial initiated in like a 60-year-old, lowering LDL by 39 milligrams per deciliter yields an approximate 22% reduction in relative risk. But having that exact same 39 milligram per esteem reduction from birth yields a greater than 50% relative risk reduction.
So the running consensus is arteriosclerosis is governed by concentration multiplied by time. Just as physicians calculate PAC years of cigarette smoking, your vascular wall experiences particle years or APOB years. Plaque does not happen because of your lipid panel on a random Tuesday in middle age. It is believed to be caused by a cumulative area under the curve across decades. But for 50 years, clinical medicine tracked LDL cholesterol, the weight of the sterile cargo instead of the particle. But if they wanted to know if it was really LDL or if it might be something else. So, specifically, they wanted to know if it might be APO-B instead of LDL. So, they looked into it.
And here's why. Every particle synthesized by the liver, whether it's LDL, VLDL, IDL, or remnants, carries on its surface exactly one single molecule of APOB100. LDLC measures the total mass of cholesterol cargo in milligrams per deciliter. AvoB directly counts the absolute number of physical particles. Remember the biophysics. Floating cholesterol molecules don't collide with or penetrate the endothelium. It's the intact lipoprotein vehicle that crosses a cell and binds via its APOB binding site. And in 2020, Tom Richardson and an international team published a landmark study in the PLUS medicine using a multivariable Mendelian randomization across more than 650,000 individuals in the UK Biobank. When analyzed individually, LDLC, triglycerides, and APOB tracked with heart disease. But when researchers placed all three into a simultaneous multivariable genetic model, the independent causal signals for LDLC and triglycerides completely vanished.
So, only APOB retain a robust, independent causal relationship with coronary artery disease. It's not the weighted lipid cargo inside the vehicle, it's the absolute concentration of the atherogenic ApoB vehicles colliding with the vascular wall. Now we arrive at the ultimate clinical question. What happens when an ordinary person in middle age is actively intervened on? Observing human genetics is one thing. Intervening in a 55-year-old living patient with decades of accumulated arterial exposure is entirely another.
Can clearing circulating particles in midlife alter clinical destiny, or is it too little, too late? To answer that, modern cardiology had to submit the lipid hypothesis to the gold standard of medicine, the double blind randomized control trial. The first definitive proof arrived in November nineteen ninety four with the publication of the Scandinavian Symvosatin Survival Study, also known as the 4S trial. The trial enrolled 4,444 patients with established coronary disease and elevated cholesterol. Simbostatin dropped LDL cholesterol by about 35%. And unlike older, nonspecific drugs, the outcome was unambiguous. Simbastatin delivered a 30% reduction in all-cause of mortality and a 42% reduction in coronary deaths.
The trial proved that intervening in middle-aged individuals with established cardiovascular disease was not futile. Lowering circulating particles actively altered survival. Now, there were many subsequent trials done after this showing similar results, but skeptics raised an intelligent, biologically grounded question. Statins don't just clear LDL, they also improve endothelial nitric oxide release, stabilize the fibrous cap. And directly reduce systemic vascular inflammation, so-called pleiotropic effects. So the critics argued: how do we know the benefit wasn't driven entirely by the anti-inflammatory stabilization of the vessel wall, with LDL reduction being a meaningless side effect? So, to prove that particle clearance was the true causal driver, medicine had to test completely different non-stat medications that clear particles via entirely different biological mechanisms with zero overlapping pleotrophic actions. The answer arrived through three landmark non-statin trials.
In 2015, the Improve It trial added azetamibe, a drug that works exclusively in the brush border of the small intestines to block cholesterol absorption. They added it to statin therapy in 18,000 patients. And azetamive has no statin pleiotropy, right, that we know of. Yet, lowering LDLC by an incremental 16 milligram per deciliter reduced cardiovascular events along the exact same proportion or slope predicted by statin trials. Then in 2017, 2018, the four-year and Odyssey Outcomes trial tested PCSK9 inhibitors, monoclonal antibodies that prevent the degradation of hepatic LDL receptors. In over 46,000 patients, these drugs drove down LDL to unprecedented physiologic lows, around 30 milligrams per deciliter, cutting major adverse cardiovascular events in direct proportion to the absolute particle reduction without an efficacy plateau.
And the final piece of the puzzle arrived in 2023 with the Clear Outcomes trial published in the New England Journal of Medicine. Researchers evaluated bempidoic acid in about 13,000 patients who are completely statin intolerant. Bempidoke acid inhibits ATP citrase lyas, two steps upstream of the H and V correctus in the liver, is a pro -drug that cannot be activated by skeletal muscle, entirely bypassing the statin muscle mechanism. In a population with zero statin exposure, bempidoic acid reduced LDL by about 21% and achieved a statistically significant 30% reduction in major adverse cardiovascular events. So, whether you block synthesis in the liver with a statin, block absorption in the testing with azetamib, upregulate receptor recycling with PC scan inhibitors, or block hepatic citrase cleavage with bemptoic acid, the clinical outcome appears to be the same. As Apo B decreases, so does your chance for heart attacks and cardiovascular events. So, where does the general academic community sit right now?
I think this consensus statement sums it up pretty well. In 2017, the European Athos Growth Society published a comprehensive consensus statement synthesizing over 200 prosecutive cohorts, genetic and menilium randomization studies, and randomized controlled trials encompassing over 2 million individuals. Their verdict was that the causality of atherogenic ABOB particles satisfies every single Bradford Hill criterion for medical causality strength of association, consistency, temporality, biological gradient, plausibility, coherence, and experimental reversibility. They felt that three completely independent scientific methods observation, Mendelian randomization, and interdimensional data, each with their own different sources for potential error and methodology, if they all point in the same direction and outcome, the probability that the finding is an artifact is virtually zero. So, in conclusion, the goal of examining this 150-year history isn't to tell you what to think, nor is it to force you to take a side in internet culture. It's to show you the breadcrumbs of science as it actually unfolded.
When you understand the evidence from the autopsy scalpel in 1852 through the biophysics of protoglycan retention to modern Mendelian randomization in clinical trials, you can start to understand why the current landscape is the way it is. But if the scientific consensus across pathology, biophysics, genetics, and clinical trials is this absolute, why does the online conversation feel more polarized today than it ever has? Well, you'll just have to tune in for my next video where I discuss that very next topic.
Disclaimer, this podcast is for entertainment, education, and informational purposes only. The topics discussed should not solely be used to diagnose, treat, or prevent any condition. The information presented here was created with an evidence-based approach, but please keep in mind that science is always changing, and at the time of listening to this, there may be some new data that makes this information incomplete or inaccurate. Always seek the advice of your personal physician or qualified healthcare provider for questions regarding any medical condition.
